Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The introduction of immune checkpoint inhibition has improved the outcomes of a subset of patients with muscle-invasive bladder cancer (MIBC); however, the majority of patients fail to respond to this approach. In this perspective, the authors describe the evidence for use of radiotherapy in combination with immune checkpoint inhibition to enhance the immunogenicity of patients' tumours and therefore enhance responsiveness to immune checkpoint inhibition in patients with advanced-stage MIBC.
